Free tool
FAERS Monitor: Vyvgart
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761195 or its brand name (Vyvgart, Efgartigimod Alfa). Reports on generic versions are filed under their own applications.
Reports
3,968
Serious
3,661
92% of reports
Hospitalization
1,915
Death reported
379
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myasthenia gravis785
- myasthenia gravis crisis455
- fatigue404
- dyspnoea301
- asthenia263
- fall224
- drug ineffective216
- urinary tract infection214
- muscular weakness199
- headache192
- death191
- dysphagia179
- off label use178
- hospitalisation175
- covid-19174
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 349 |
| 2023 | 1,194 |
| 2024 | 1,669 |
| 2025 | 451 |
| 2026 | 297 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,191 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myasthenia gravis crisisSignal | 455 | 2348.0 | 2112.1 | 738,365 |
| myasthenia gravisSignal | 785 | 570.5 | 533.6 | 402,561 |
| dysphagiaSignal | 179 | 10.0 | 8.7 | 1,447 |
| muscular weaknessSignal | 199 | 9.3 | 8.1 | 1,470 |
| urinary tract infectionSignal | 214 | 6.7 | 5.8 | 1,030 |
| hospitalisationSignal | 175 | 6.0 | 5.2 | 736 |
| covid-19Signal | 174 | 5.3 | 4.5 | 601 |
| astheniaSignal | 263 | 3.7 | 3.3 | 527 |
| fallSignal | 224 | 3.6 | 3.1 | 418 |
| dyspnoeaSignal | 301 | 2.8 | 2.5 | 361 |
| fatigueSignal | 404 | 2.8 | 2.5 | 466 |
| headache | 192 | 1.6 | 1.4 | 47 |
| death | 191 | 1.2 | 1.0 | 5 |
| off label use | 178 | 1.1 | 0.9 | 1 |
| drug ineffective | 216 | 0.9 | 0.8 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.